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A revised edition of the core diagnostic text, Classification of
Tumours of Haematopoietic and Lymphoid Tissues, has recently
been published by the World Health Organization (WHO) in
collaboration with the European Association for Haematopatho-
logy, the Society for Hematopathology and a panel of 30 inter-
nationally renowned scientists and haematologists. Haematological
neoplasms were first included in the Third Edition of the WHO
series on histological and genetic typing of human tumours in 2001
and heralded a significant change in practice and a much-needed
harmonisation of what was becoming an increasingly complex
myriad of different diagnostic classification systems. This new
edition includes the diagnostic criteria for newly characterised
neoplasms and incorporates revised information for previously
classified neoplasms in light of recently identified additional
scientific and clinical knowledge. As in the previous edition, the
data are presented in a strictly disease-oriented manner and
clinical information, diagnostic criteria, pathological features and
associated recurrent genetic aberrations are detailed.
The WHO classification of lymphoid neoplasms was initially
largely based on the Revised European–American Lymphoma
Classification (REAL), the most widely used monograph before
2001. In the revision, due credence has been given to the fact that
the presence or absence of certain translocations in B lympho-
blastic leukaemia/lymphoma carries such prognostic significance
that it is now appropriate to subdivide this entity based largely on
specific recurring chromosomal anomalies into seven distinct
subgroups, with an eighth group for those remaining cases not
meeting the defining criteria for any of the seven other subgroups.
The WHO classification of myeloid neoplasms integrated ideas
from a variety of sources, including the French–American–British
Cooperative Group classification (FAB) and the Polycythaemia Vera
Study Group (PVSG), and also added a number of novel concepts
and classifications, including a lowering of the required blast
percentage threshold to diagnose acute myeloid leukaemia from 30%
to 20% and the creation of four defined subgroups of acute myeloid
leukaemia: (i) acute myeloid leukaemia with recurrent genetic
abnormalities, (ii) acute myeloid leukaemia with multilineage
dysplasia (now renamed acute myeloid leukaemia with myelodys-
plasia-related changes), (iii) therapy-related acute myeloid leukae-
mia and myelodysplastic syndrome, and (iv) acute myeloid
leukaemia not otherwise categorised for those cases not meeting
the criteria for any of the other subgroups. The new edition includes
further revision and refinement in light of an increasing body of
research identifying prognostic significance to new and previously
identified recurrent genetic anomalies. By the addition of more
recurrent cytogenetic anomalies to the list, the group of cases that
would previously have fallen into the ‘not otherwise categorised’
subgroup has reduced significantly. In recognition of the fact that
the body of literature regarding the significance of certain genetic
aberrations is not yet mature, provisional entries have also been
featured. There has been clarification of leukaemias with features
of both myeloid and lymphoid leukaemia in that a new category
of ‘acute leukaemia of ambiguous lineage’ has been added and
the defining criteria for diagnosis of what would have previously
been called bilineal or biphenotypic leukaemia have been altered.
Similarly, there has been renaming and refinement of the
classification of myelodysplastic syndromes in the new edition; the
presence of ring sideroblasts is no longer considered to be significant
in the presence of multilineage dysplasia, refractory cytopaenia
with unilineage dysplasia replaces the host of cytopaenic-
lineage-specific diagnoses and a provisional entry of ‘refractory
cytopaenia of childhood’ has also been entered. A new category of
‘myeloid/lymphoid neoplasms with eosinophilia and PDGRFB
rearrangement’ has been created within the myeloproliferative/
myelodyplastic disorders classification and significant changes have
been made within the myeloproliferative disorders diagnostic
classification (now termed myeloproliferative neoplasms in recogni-
tion of the malignant nature of these disorders). Appropriate
emphasis has been placed on the presence of the JAK2 V617F and
similar activating mutations in parallel with recent clinical practice.
Additional clinical and laboratory criteria are also offered to
facilitate diagnosis and subclassification.
With the publication of the previous edition of the WHO
Classification of Tumours of Haematopoietic and Lymphoid
Tissues, the provision of an authoritative, concise reference book
provided an international standard for haematologists and
histopathologists. This finally permitted easy comparison of data
between countries and continents, and the book quickly became an
invaluable manual both in routine clinical practice and when
designing studies to monitor response to treatment and clinical
outcome. The refinements in the new edition reflect the fact that
for any classification system to remain up to date and relevant, a
regular account of recently published, high-quality, peer-reviewed
data needs to be given. By carefully fine-tuning the diagnostic
criteria for those categories previously recognised and consi-
dered, and by creating diagnostic standards for those conditions
recently identified, it will be possible to diagnose patients more
accurately, design trials looking at outcomes in a less hetero-
geneous population and ultimately, therefore, facilitate a greater
understanding of the molecular basis for these conditions. In all, it
is an invaluable text for scientists, pathologists and clinicians alike.
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